NCI 10066: A phase 1 / 2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.tps4137
Abstract: TPS4137Background: Gastric cancer remains a significant health problem in the US and globally with more than 951,600 annual cases worldwide. Moreover, the incidence of GEJ-centered adenocarcinoma i... read more here.
Keywords: nci 10066; 10066 phase; olaparib combination; study olaparib ... See more keywords
Antitumor effects and mechanisms of olaparib in combination with carboplatin and BKM120 on human triple-negative breast cancer cells
Sign Up to like & getrecommendations! Published in 2018 at "Oncology Reports"
DOI: 10.3892/or.2018.6716
Abstract: Triple-negative breast cancer (TNBC) refers to a heterogeneous group of tumors, for which there is currently a lack of targeted therapies. Poly(ADP-ribose) polymerase (PARP) inhibitors, phosphatidylinositol 3-kinase (PI3K) inhibitors and carboplatin (CBP) have demonstrated sufficient… read more here.
Keywords: combination; negative breast; bkm120; breast cancer ... See more keywords